Cancer drug discovery preclinical research
Web page: Not specified
Funding details: Related items
Projects: NMTrypI - New Medicines for Trypanosomatidic Infections, Mass spectrometry proteomics for biomarker discovery, Thymidylate synthase dimer dissociation, BioTarget Database, Compound Data
Institutions: Università degli Studi di Modena e Reggio Emilia (UNIMORE)
https://orcid.org/0000-0002-0443-5402
Projects: Mass spectrometry proteomics for biomarker discovery, Supplementary Information 2 associated with the manuscript entitled " Label free Mass spectrometry proteomics reveals different pathways modulated in THP-1 cells infected with therapeutic failure and drug resistance Leishmania infantum clinical isolates", Supplementary Information 2 associated with the manuscript entitled "Label free Mass spectrometry proteomics reveals different pathways modulated in THP-1 cells infected with therapeutic failure and drug resistance Leishmania infantum clinical isolates", MS identification of L infantum proteins related to their drug resistance patterns for new drug targets identification and ecotoxicological evaluations of their environmental and interspecies impact, Enhanced Anticancer Effect of Thymidylate Synthase Dimer Disrupters Promoting Intracellular Accumulation, Biochemical characterization of the feedforward loop between CDK1 and FOXM1 in epidermal stem cells, Drug Discovery and Biotechnology Standard Operating Procedures
Institutions: Università degli Studi di Modena e Reggio Emilia (UNIMORE), Università di Modena e Reggio Emilia
https://orcid.org/0000-0002-7244-7106
Junior researcher in Medicinal Chemistry
Projects: de.NBI-SysBio, Kinetics on the move - Workshop 2016, Example use cases, SBEpo - Systems Biology of Erythropoietin, FAIRDOM & LiSyM & de.NBI Data Structuring Training, FAIRDOM, EnzymeML, GMDS Project Group "FAIRe Dateninfrastrukturen für die Biomedizinische Informatik", FAIRDOM Community Workers, MIX-UP, COVID-19 Disease Map, ERNEST Mapping Group Pilot Study, NMTrypI - New Medicines for Trypanosomatidic Infections, Standardization of enzyme-catalyzed reaction measurement, Standardization of enzyme-catalyzed reaction modelling, ModeleXchange initiative, CoVIDD - Coronavirus interactions in drug discovery - optimization and implementation, Mass spectrometry proteomics for biomarker discovery, Thymidylate synthase dimer dissociation, WG1 - Compound libraries coordination and integration of compound design, WG2 - Integration of early phase studies and low environmental impact actions, WG3 - Coordination of in vitro-to-in vivo translation of OneHealth leads and candidates, WG4 - Integration of R&D process-environmental studies and translation in informed whitepaper, WG5 - Promote dissemination, WG6 - Promote the transfer of knowledge, SABIO-VIS, SDBV/HITS, BioTarget Database, Compound Data
Institutions: Heidelberg Institute for Theoretical Studies
https://orcid.org/0000-0002-9077-5664
Programme: Cancer drug discovery preclinical research
Public web page: Not specified
Programme: Cancer drug discovery preclinical research
Public web page: Not specified
The Hippo signalling is a metabolic control pathway of cells proliferation and apoptosis, thus represents an emerging topic in tumour suppression regulation and regenerative medicine. This pathway is activated by anti-proliferative signals which come from the extracellular environment received by membranes proteins. In the cytosol compartment, the pathway is regulated by a phosphorylation cascade of four main proteins with Serin-Treonin kinase activity. At the end-point of this cascade the ...
Programme: Cancer drug discovery preclinical research
Public web page: Not specified
ROR ID: https://ror.org/01f7bcy98
Department: Not specified
Country: 
Germany
City: Heidelberg
Web page: https://www.h-its.org
ROR ID: Not specified
Department: Not specified
Country: 
Italy
City: Modena
Web page: https://www.unimore.it/
Creator: Lorenzo Tagliazucchi
Submitter: Lorenzo Tagliazucchi
Semi-targeted Mass Spectrometry proteomics study to detect 12 selected proteins of two serum samples belonging to the FOLFOX-4 study on heavly-pretreated ovarian cancer patients. The two samples, F10 and F12, are basal samples collected at before the first FOLFOX-4 treatment cycle (T0) and were selected for this study because they show a different proteome profile.
DownloadSupplementary material for "Mass spectrometry proteomic and network enrichment analysis to track FOLFOX response in drug resistant ovarian carcinoma"
